A Phase 1/2 interventional study of Gemcitabine and Albumin-bound paclitaxel in Metastatic Pancreatic Cancer, sponsored by Celgene. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-22.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 369 studies testing gemcitabine in Pancreatic Neoplasms — 29 open to participants now, 44 under way, 5 of them phase 3. Gemcitabine · Pancreatic Neoplasms.
Among the 369 studies testing gemcitabine in Pancreatic Neoplasms, this one is the 100th largest by enrollment of the 352 interventional ones that give a count, is one of 26 that started in 2006, is one of 38 in phase 1/2, and was the 99th registered.
3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.
Browse Pancreatic Neoplasms studies →29 of the 369 studies testing gemcitabine in Pancreatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Revolution Medicines, Inc. · Sites in United States
Ages 18+
Smartwise Sweden AB · Sites in Sweden
Ages 18+
Revolution Medicines, Inc. · Sites in United States, Australia, Austria and 18 more countries
Ages 18+
Shanghai Hengrui Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
369 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 125 · Phase 2 238 · Phase 3 36 · Phase 4 2
First in 1995; this study’s year is marked. 26 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 67 is above the median of 47 across 2,932 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 37 across the 352 interventional studies. Of the 268 that completed or were terminated, 80 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 369 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
27 studies in Pancreatic Neoplasms by Bristol-Myers Squibb: 3 open now, 5 under way, 1 of them phase 3. Of 22 finished, 10 (45%) have results posted.
Among the 27 studies in Pancreatic Neoplasms by Bristol-Myers Squibb, this one is the 15th largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2006, is one of 6 in phase 1/2, and was the 4th registered.
Bristol-Myers Squibb’s Pancreatic Neoplasms studies by the year they started, since 2005.
15 of the studies testing gemcitabine in Pancreatic Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06953999Phase 3AkesoA Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer | 2027-05-14 |
| NCT02340117SynerGene Therapeutics, Inc.Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer | 2026-12 |
| NCT03652428University of Maryland, BaltimorePhase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC) | 2026-12-31 |
| NCT04115163Anne NoonanBiologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer | 2026-12-31 |
| NCT04894643EBG MedAustron GmbHPreoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 369 studies testing gemcitabine in Pancreatic Neoplasms, from their registry updates:
Among Bristol-Myers Squibb’s 27 in Pancreatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To determine the maximum tolerated dose and dose-limiting toxicity of Gemcitabine plus Albumin-bound paclitaxel (ABI-007) in patients with advanced metastatic pancreatic cancer.
Albumin-bound paclitaxel is a novel, solvent-free, albumin-bound, 130 nanometer particle form of paclitaxel designed to avoid the problems associated with solvents used in Taxol(Abraxane prescribing information 2005). Albumin has a number of properties that make it an attractive molecule to combine with paclitaxel. Albumin is a natural transporter of endogenous hydrophobic molecules such as water-insoluble vitamins and hormones (Vorum 1999)and albumin binding to the gp-60 receptor (albondin) initiates the caveolae-mediated endothelial transport of protein-bound and unbound plasma constituents (John et al 2003, Minshall et al 2003, Tiruppathi et al 1997).
This study consisted of a Phase 1 dose escalation phase, a Phase 2 treatment phase and a 24-month follow-up phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or non-pregnant and non-lactating female, and age greater or equal to 18.
Patient has the following blood counts at baseline
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received albumin-bound paclitaxel 100 mg/m\^2 followed by gemcitabine 1000 mg/m\^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle (dose level one). Treatment continued until progressive disease or unacceptable toxicity.
Drug: Gemcitabine · Drug: Albumin-bound paclitaxel
Participants received albumin-bound paclitaxel 125 mg/m\^2 followed by gemcitabine 1000 mg/m\^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle (dose level two). Treatment continued until progressive disease or unacceptable toxicity.
Drug: Gemcitabine · Drug: Albumin-bound paclitaxel
Participants received albumin-bound paclitaxel 150 mg/m\^2 followed by gemcitabine 1000 mg/m\^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle (dose level three). Treatment continued until progressive disease or unacceptable toxicity.
Drug: Gemcitabine · Drug: Albumin-bound paclitaxel
Administered by intravenous infusion over 30 minutes.
Also known as: Gemzar®
Administered by intravenous infusion over 30 minutes.
Also known as: ABI-007, ABRAXANE®
Number of Participants With Dose-limiting Toxicities
A dose-limiting toxicity (DLT) is defined as one or more of the following toxicities related to study drug during Cycle 1, according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), Version 3: * Grade 4 neutropenia lasting \>3 days in the absence of growth factor support; * Grade 4 neutropenia associated with fever \>38.5°C; * Any other Grade 4 hematological toxicity; * Grade 3 thrombocytopenia with hemorrhage; * Grade 3 or 4 nausea, vomiting or diarrhea despite prophylaxis or treatment with an optimal anti-emetic or anti-diarrhea regimen; * Any other Grade 3 or higher non-hematological toxicity attributable to the study drug, excluding alopecia and fatigue.
Time frame: Cycle 1 (Days 1-28)
Number of Participants With Adverse Events (AE)
An AE was any untoward medical occurrence, not necessarily having a causal relationship with the patient's treatment, that began or worsened in grade after the start of study drug through 30 days after the last dose. A serious AE (SAE) is any untoward medical occurrence that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. Treatment-related AEs (TRAEs) include those assessed by the Investigator as possibly, probably, or definitely related to study treatment. Severity was graded according to the NCI CTCAE based on the following: Grade 1- Mild; Grade 2 -Moderate; Grade 3 - Severe; Grade 4 - Life-threatening or disabling; Grade 5 - Death related to AE.
Time frame: Up to 25 months
Percentage of Participants Who Achieved an Objective Confirmed Overall Response
Overall Response is defined as the percent of participants who achieve an objective confirmed complete (CR) or partial response (PR). Response was determined according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, assessed by an Independent Radiological Reviewer. CR: The disappearance of all known disease and no new sites or disease-related symptoms confirmed at least 4 weeks after initial documentation. All sites must be assessed, including non-measurable sites, such as effusions, or markers. PR: At least a 30% decrease in the sum of the longest diameters of target lesions, taking as a reference the baseline sum of the longest diameters confirmed at least 4 weeks after initial documentation and no new non-target lesions and/or unequivocal progression of existing non-target lesions. PR is also recorded when all measurable disease has completely disappeared, but a non-measurable component (i.e., ascites) is still present but not progressing.
Time frame: Up to approximately 4 years
Percentage of Participants With Disease Control
Disease control is defined as participants with Stable Disease for at least 16 weeks, or confirmed complete or partial overall response, based on RECIST guidelines and assessed by an Independent Radiological Reviewer. Stable disease is defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for Progressive Disease, and no new non-target lesions or unequivocal progression of existing non-target lesions. Progressive Disease is defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.
Time frame: Up to approximately 4 years
Progression-free Survival
Progression-free survival is defined as the time from first dose of study drug to the start of disease progression or patient death, whichever occurs first, assessed by an Independent Radiological Reviewer. Participants who do not have disease progression or have not died were censored at the last known time that the participant was progression free. Progression-free survival was summarized using Kaplan-Meier methods. Progressive Disease is defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.
Time frame: Up to approximately 4 years
Duration of Response
Duration of response was assessed by progression-free survival for participants who achieved a confirmed Complete Response or Partial Response, assessed by an Independent Radiological Reviewer.
Time frame: Up to approximately 4 years
Overall Survival
Overall survival was defined as the time from the date of first dose of study drug to the date of patient death from all causes. Participants who did not die were censored at the last known time the patient was alive. Patient survival was summarized using Kaplan-Meier methods.
Time frame: Up to approximately 4 years
Maximal Degree of Myelosuppression
The maximal degree of myelosuppression was assessed by the overall nadir of absolute neutrophil count (ANC), white blood cell count and platelet count based on clinical laboratory measurements.
Time frame: During the treatment phase, up to a maximum of 24 months.
Maximal Degree of Anemia
The maximal degree of anemia (and myelosuppression) was assessed by the overall (any time after first dose of study drug) nadir of hemoglobin levels based on clinical laboratory measurements.
Time frame: During the treatment phase, up to a maximum of 24 months.
Enrollment was initiated in November 2006 and completed in September 2008. Sixty-seven patients were enrolled at four sites in the US.
| Milestone | 100 mg/m^2 | 125 mg/m^2 | 150 mg/m^2 |
|---|---|---|---|
| Started | 20 | 44 | 3 |
| Phase 1, dose escalation population | 20 | 7 | 3 |
| Completed | 11 | 21 | 1 |
| Not completed | 9 | 23 | 2 |
| Withdrew: Unacceptable toxicity | 2 | 8 | 2 |
| Withdrew: Adverse event | 1 | 4 | 0 |
| Withdrew: Physician decision | 1 | 4 | 0 |
| Withdrew: Withdrawal by subject | 5 | 7 | 0 |
A dose-limiting toxicity (DLT) is defined as one or more of the following toxicities related to study drug during Cycle 1, according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), Version 3: * Grade 4 neutropenia lasting \>3 days in the absence of growth factor support; * Grade 4 neutropenia associated with fever \>38.5°C; * Any other Grade 4 hematological toxicity; * Grade 3 thrombocytopenia with hemorrhage; * Grade 3 or 4 nausea, vomiting or diarrhea despite prophylaxis or treatment with an optimal anti-emetic or anti-diarrhea regimen; * Any other Grade 3 or higher non-hematological toxicity attributable to the study drug, excluding alopecia and fatigue.
| participants | 100 mg/m^2 | 125 mg/m^2 | 150 mg/m^2 |
|---|---|---|---|
| Number of Participants With Dose-limiting Toxicities | 4 | 0 | 1 |
An AE was any untoward medical occurrence, not necessarily having a causal relationship with the patient's treatment, that began or worsened in grade after the start of study drug through 30 days after the last dose. A serious AE (SAE) is any untoward medical occurrence that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. Treatment-related AEs (TRAEs) include those assessed by the Investigator as possibly, probably, or definitely related to study treatment. Severity was graded according to the NCI CTCAE based on the following: Grade 1- Mild; Grade 2 -Moderate; Grade 3 - Severe; Grade 4 - Life-threatening or disabling; Grade 5 - Death related to AE.
| participants | 100 mg/m^2 | 125 mg/m^2 | 150 mg/m^2 |
|---|---|---|---|
| Patients with at least 1 AE | 20 | 44 | 3 |
| At least 1 grade 3 or higher AE | 15 | 42 | 3 |
| At least 1 treatment-related AE | 18 | 42 | 3 |
| At least 1 treatment-related grade 3 to 5 AE | 11 | 38 | 3 |
| Patients with at least 1 SAE | 10 | 24 | 1 |
| Patients with at least 1 treatment-related SAE | 4 | 12 | 1 |
| At least 1 AE and drug permanently discontinued | 3 | 12 | 2 |
| At least 1 TRAE and drug permanently discontinued | 2 | 8 | 2 |
| At least 1 dose reduction due to TRAE | 4 | 10 | 1 |
| At least 1 dose interruption due to AE | 1 | 0 | 0 |
| At least 1 treatment-related AE dose interruption | 1 | 0 | 0 |
| At least 1 treatment-emergent dose delay due to AE | 14 | 27 | 3 |
| At least 1 treatment-related dose delay due to AE | 13 | 27 | 3 |
| At least 1 AE resulting in death | 0 | 1 | 1 |
Overall Response is defined as the percent of participants who achieve an objective confirmed complete (CR) or partial response (PR). Response was determined according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, assessed by an Independent Radiological Reviewer. CR: The disappearance of all known disease and no new sites or disease-related symptoms confirmed at least 4 weeks after initial documentation. All sites must be assessed, including non-measurable sites, such as effusions, or markers. PR: At least a 30% decrease in the sum of the longest diameters of target lesions, taking as a reference the baseline sum of the longest diameters confirmed at least 4 weeks after initial documentation and no new non-target lesions and/or unequivocal progression of existing non-target lesions. PR is also recorded when all measurable disease has completely disappeared, but a non-measurable component (i.e., ascites) is still present but not progressing.
| percentage of participants | 100 mg/m^2 | 125 mg/m^2 | 150 mg/m^2 |
|---|---|---|---|
| Percentage of Participants Who Achieved an Objective Confirmed Overall Response | 25 (8.7 to 49.1) | 39 (24.2 to 53.0) | 0 (NA to NA) |
Disease control is defined as participants with Stable Disease for at least 16 weeks, or confirmed complete or partial overall response, based on RECIST guidelines and assessed by an Independent Radiological Reviewer. Stable disease is defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for Progressive Disease, and no new non-target lesions or unequivocal progression of existing non-target lesions. Progressive Disease is defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.
| percentage of participants | 100 mg/m^2 | 125 mg/m^2 | 150 mg/m^2 |
|---|---|---|---|
| Percentage of Participants With Disease Control | 55 (33.2 to 76.8) | 55 (39.8 to 69.3) | 33 (0.8 to 90.6) |
Progression-free survival is defined as the time from first dose of study drug to the start of disease progression or patient death, whichever occurs first, assessed by an Independent Radiological Reviewer. Participants who do not have disease progression or have not died were censored at the last known time that the participant was progression free. Progression-free survival was summarized using Kaplan-Meier methods. Progressive Disease is defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.
| months | 100 mg/m^2 | 125 mg/m^2 | 150 mg/m^2 |
|---|---|---|---|
| Progression-free Survival | 6.1 (3.7 to NA) | 6.9 (4.8 to 9.2) | 1.6 (0.5 to 10.0) |
Duration of response was assessed by progression-free survival for participants who achieved a confirmed Complete Response or Partial Response, assessed by an Independent Radiological Reviewer.
| months | 100 mg/m^2 | 125 mg/m^2 | 150 mg/m^2 |
|---|---|---|---|
| Duration of Response | NA (2.4 to NA) | 7.3 (5.5 to 21.9) | — |
Overall survival was defined as the time from the date of first dose of study drug to the date of patient death from all causes. Participants who did not die were censored at the last known time the patient was alive. Patient survival was summarized using Kaplan-Meier methods.
| months | 100 mg/m^2 | 125 mg/m^2 | 150 mg/m^2 |
|---|---|---|---|
| Overall Survival | 9.3 (6.6 to 11.9) | 12.2 (8.9 to 17.9) | 6.1 (0.5 to 17.9) |
The maximal degree of myelosuppression was assessed by the overall nadir of absolute neutrophil count (ANC), white blood cell count and platelet count based on clinical laboratory measurements.
| x10^9/L | 100 mg/m^2 | 125 mg/m^2 | 150 mg/m^2 |
|---|---|---|---|
| Absolute neutrophil count | 1.38 ± 1.541 | 0.96 ± 1.446 | 0.47 ± 0.460 |
| White blood cell count | 2.69 ± 1.734 | 2.18 ± 1.849 | 1.52 ± 1.484 |
| Platelet count | 120.3 ± 79.02 | 88.3 ± 62.10 | 58.7 ± 48.64 |
The maximal degree of anemia (and myelosuppression) was assessed by the overall (any time after first dose of study drug) nadir of hemoglobin levels based on clinical laboratory measurements.
| g/L | 100 mg/m^2 | 125 mg/m^2 | 150 mg/m^2 |
|---|---|---|---|
| Maximal Degree of Anemia | 95.1 ± 12.85 | 91.8 ± 10.43 | 95.3 ± 15.37 |
Collected over Adverse events were collected up to 30 days after the last dose (a maximum of 25 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 100 mg/m^2 | — | 10/20 (50%) | 20/20 (100%) |
| 125 mg/m^2 | — | 24/44 (54.5%) | 44/44 (100%) |
| 150 mg/m^2 | — | 1/3 (33.3%) | 3/3 (100%) |
| Event | 100 mg/m^2 | 125 mg/m^2 | 150 mg/m^2 |
|---|---|---|---|
| SepsisInfections and infestations | 0/20 | 0/44 | 1/3 |
| PainGeneral disorders | 2/20 | 0/44 | 0/3 |
| DehydrationMetabolism and nutrition disorders | 2/20 | 3/44 | 0/3 |
| PyrexiaGeneral disorders | 1/20 | 3/44 | 0/3 |
| PneumoniaInfections and infestations | 1/20 | 2/44 | 0/3 |
| Neutropenic sepsisInfections and infestations | 1/20 | 1/44 | 0/3 |
| Urinary tract infectionInfections and infestations | 1/20 | 0/44 | 0/3 |
| DiarrhoeaGastrointestinal disorders | 1/20 | 1/44 | 0/3 |
| Duodenal obstructionGastrointestinal disorders | 1/20 | 0/44 | 0/3 |
| NauseaGastrointestinal disorders | 1/20 | 0/44 | 0/3 |
| Event | 100 mg/m^2 | 125 mg/m^2 | 150 mg/m^2 |
|---|---|---|---|
| FatigueGeneral disorders | 15/20 | 39/44 | 3/3 |
| AlopeciaSkin and subcutaneous tissue disorders | 15/20 | 35/44 | 1/3 |
| AnaemiaBlood and lymphatic system disorders | 12/20 | 30/44 | 2/3 |
| LeukopeniaBlood and lymphatic system disorders | 4/20 | 18/44 | 2/3 |
| NeutropeniaBlood and lymphatic system disorders | 10/20 | 25/44 | 2/3 |
| ThrombocytopeniaBlood and lymphatic system disorders | 5/20 | 26/44 | 2/3 |
| Abdominal painGastrointestinal disorders | 7/20 | 17/44 | 2/3 |
| DiarrhoeaGastrointestinal disorders | 7/20 | 23/44 | 2/3 |
| NauseaGastrointestinal disorders | 8/20 | 29/44 | 2/3 |
| VomitingGastrointestinal disorders | 5/20 | 20/44 | 2/3 |
| Age, Continuous(years) | 100 mg/m^2 | 125 mg/m^2 | 150 mg/m^2 | Total |
|---|---|---|---|---|
| Median | 62.0 (30 to 86) | 61.5 (28 to 78) | 69.0 (53 to 72) | 62.0 (28 to 86) |
| Sex: Female, Male(Participants) | 100 mg/m^2 | 125 mg/m^2 | 150 mg/m^2 | Total |
|---|---|---|---|---|
| Female | 9 | 25 | 1 | 35 |
| Male | 11 | 19 | 2 | 32 |
| Race/Ethnicity, Customized(participants) | 100 mg/m^2 | 125 mg/m^2 | 150 mg/m^2 | Total |
|---|---|---|---|---|
| Asian | 1 | 1 | 0 | 2 |
| Black, of African Heritage | 0 | 2 | 0 | 2 |
| White, Non-Hispanic, and Non-Latino | 16 | 37 | 1 | 54 |
| White, Hispanic, or Latino | 2 | 4 | 2 | 8 |
| Other | 1 | 0 | 0 | 1 |
| Region of Enrollment(participants) | 100 mg/m^2 | 125 mg/m^2 | 150 mg/m^2 | Total |
|---|---|---|---|---|
| United States | 20 | 44 | 3 | 67 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | 100 mg/m^2 | 125 mg/m^2 | 150 mg/m^2 | Total |
|---|---|---|---|---|
| 0 (Fully Active) | 9 | 22 | 2 | 33 |
| 1 (Restrictive but Ambulatory) | 11 | 22 | 1 | 34 |
| Histology of Primary Diagnosis: Adenocarcinoma(participants) | 100 mg/m^2 | 125 mg/m^2 | 150 mg/m^2 | Total |
|---|---|---|---|---|
| Number | 20 | 44 | 3 | 67 |
| Time from First Documented Metastasis/Relapse to Study Entry(months) | 100 mg/m^2 | 125 mg/m^2 | 150 mg/m^2 | Total |
|---|---|---|---|---|
| Median | 0.8 (0 to 11) | 0.7 (0 to 13) | 0.3 (0 to 1) | 0.7 (0 to 13) |
| Current Site(s) of Metastasis/Relapse(participants) | 100 mg/m^2 | 125 mg/m^2 | 150 mg/m^2 | Total |
|---|---|---|---|---|
| Skin/Soft Tissue | 0 | 1 | 0 | 1 |
| Supraclavicular Nodes | 0 | 2 | 0 | 2 |
| Axilla | 2 | 0 | 0 | 2 |
| Bone | 1 | 3 | 0 | 4 |
| Lung/Thoracic | 5 | 18 | 1 | 24 |
| Liver | 11 | 33 | 2 | 46 |
| Abdomen/Peritoneum | 16 | 37 | 1 | 54 |
| Pelvis | 1 | 3 | 1 | 5 |
| Other | 8 | 6 | 0 | 14 |
1 further baseline measures are reported on the registry.
Ran from Nov 2006 to primary completion in Sep 2008, 22 months.
Results were first posted in Aug 2013, 4 years 11 months after primary completion.
Of 114 industry-sponsored phase 1/2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 88. This study's 22 months is below that.
Counting every sponsor, half of 208 studies reached it within 51 months; a quarter within 36 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Gemcitabine · Albumin-Bound Paclitaxel